Managing HER2+ Early Breast Cancer: Insights and Future Horizons
Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.
Navigating HER2+ Early Breast Cancer: Insights Into the Current Treatment Landscape
In this companion article, Sandra M. Swain, MD, FACP, FASCO, provides insights into effective management of patients with early-stage HER2+ breast cancer and reviews recent data in the evolving treatment landscape.
Oh Discusses Goals of Treatment in Patients With Cytopenic Myelofibrosis
During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen T. Oh, MD, PhD, discussed with participants when they would use pacritinib for patients with thrombocytopenia related to myelofibrosis.
Trials Support Use of Momelotinib After JAK Inhibition for Anemic MF
During a Targeted Oncology™ Case-Based Roundtable™ event, Salman Fazal, MD, discussed data from the SIMPLIFY-2 and MOMENTUM trials of momelotinib for patients with myelofibrosis. This is the second of 2 articles based on this event.
MANIFEST-2 Meets Primary End Point With Pelabresib Plus Ruxolitinib in MF
Along with improvements shown for the primary and secondary end points of the phase 3 MANIFEST-2 trial in JAK inhibitor-naive patients with myelofibrosis, pelabresib plus ruxolitinib did not display any new safety signals.
JAK2 Inhibition’s Role in Newly Diagnosed Myelofibrosis
At a live virtual event, Jeanne Palmer, MD, provided commentary on the development of myeloproliferative neoplasms in patients, particularly those with newly diagnosed aggressive myelofibrosis.
2 Clarke Drive Cranbury, NJ 08512